STRATA Skin Sciences Hits 52-Week Low at $1.24 Amid Financial Struggles

STRATA Skin Sciences, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.24 on November 21, 2025. This marks a significant decline, with the stock's performance over the past year showing a decrease of 57.77%, starkly contrasting with the S&P 500's gain of 11.0% during the same period.
The company's market capitalization stands at approximately USD 9 million, reflecting its microcap status. STRATA has faced challenges, including a negative return on equity of -767.90% and a debt-to-equity ratio of 9.61, indicating a high level of debt relative to its equity. The stock's price-to-book ratio is reported at 9.17, suggesting that the market values the company significantly higher than its book value.

In terms of operational performance, STRATA has reported operating losses, with a five-year annual growth rate of operating profit at -33.37%. The company's ability to service its debt appears weak, as evidenced by a poor EBIT to interest ratio of -4.08. Overall, STRATA Skin Sciences, Inc. is navigating a challenging financial landscape, reflected in its recent stock performance.